IFNAR1 and neoplasm: This was shown by inhibiting the interferon-1 pathway by blocking interferon-α/β receptor-1 (IFNAR-1) with an antibody during CPA treatment, which greatly inhibited immune cell infiltration, leading to a lack of tumor regression.